Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Clayton

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Neuroimage. Clinical|July 12, 2021
PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease-causing Presenilin-1 E280A mutation carriersValentina Ghisays, Francisco Lopera, Dhruman D Goradia, et al.
Nature|September 10, 2010
A trans-acting locus regulates an anti-viral expression network and type 1 diabetes riskMatthias Heinig, Enrico Petretto, Chris Wallace, et al.
The Lancet. Neurology|January 24, 2026
Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1<sup>Glu280Ala</sup> mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trialPierre N Tariot, Francisco S Lopera, Silvia Ríos-Romenets, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Neuroimage. Clinical|July 12, 2021
PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease-causing Presenilin-1 E280A mutation carriersValentina Ghisays, Francisco Lopera, Dhruman D Goradia, et al.
Nature|September 10, 2010
A trans-acting locus regulates an anti-viral expression network and type 1 diabetes riskMatthias Heinig, Enrico Petretto, Chris Wallace, et al.
The Lancet. Neurology|January 24, 2026
Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1<sup>Glu280Ala</sup> mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trialPierre N Tariot, Francisco S Lopera, Silvia Ríos-Romenets, et al.
Pageof 7